J. Clark

发表

Benzhydrylquinazolinediones: novel cytosolic phospholipase A2alpha inhibitors with improved physicochemical properties.

J. D. Clark, J. McKew, J. Xiang, 2009, Bioorganic & medicinal chemistry.

Parsing the Interferon Transcriptional Network and Its Disease Associations

Chun Jimmie Ye, N. Hacohen, A. Regev, 2016, Cell.

The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis.

J. D. Clark, J. Telliez, M. Dowty, 2016, Clinical and experimental rheumatology.

Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases.

Mark J. Mitton-Fry, J. D. Clark, M. Hegen, 2018, Journal of medicinal chemistry.

Reversibility of peripheral blood leukocyte phenotypic and functional changes after exposure to and withdrawal from tofacitinib, a Janus kinase inhibitor, in healthy volunteers.

J. D. Clark, P. Biswas, K. Weinhold, 2018, Clinical immunology.

Indole cytosolic phospholipase A2 alpha inhibitors: discovery and in vitro and in vivo characterization of 4-{3-[5-chloro-2-(2-{[(3,4-dichlorobenzyl)sulfonyl]amino}ethyl)-1-(diphenylmethyl)-1H-indol-3-yl]propyl}benzoic acid, efipladib.

J. D. Clark, M. Hegen, J. McKew, 2008, Journal of medicinal chemistry.

A novel arachidonic acid-selective cytosolic PLA2 contains a Ca2+-dependent translocation domain with homology to PKC and GAP

J. D. Clark, R. Kriz, C. Ramesha, 1991, Cell.

Crystal Structure of Human Cytosolic Phospholipase A2 Reveals a Novel Topology and Catalytic Mechanism

J. D. Clark, W. Somers, M. Stahl, 1999, Cell.

MILBEMYCIN OXIME (INTERCEPTOR) TREATMENT OF AMPHIPOD PARASITES (HYPERIIDAE) FROM SEVERAL HOST JELLYFISH SPECIES

J. D. Clark, A. Stark, Malissa Smith, 2015, Journal of zoo and wildlife medicine : official publication of the American Association of Zoo Veterinarians.

Effect of perzinfotel and a proprietary phospholipase A(2) inhibitor on kinetic gait and subjective lameness scores in dogs with sodium urate-induced synovitis.

S. Budsberg, J. D. Clark, B. Torres, 2011, American journal of veterinary research.

Selective functional inhibition of JAK-3 is sufficient for efficacy in collagen-induced arthritis in mice.

Xin Xu, Mary Collins, Maria L Webb, 2010, Arthritis and rheumatism.

Attenuating Janus Kinases (JAK) by Tofacitinib Effectively Prevented Psoriasis Pathology in Various Mouse Skin Inflammation Models

S. Rahman, J. D. Clark, M. Hegen, 2013 .

Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases.

Mark E Flanagan, J. D. Clark, J. Telliez, 2014, Journal of medicinal chemistry.

Contribution of a European‐Prevalent Variant near CD83 and an East Asian–Prevalent Variant near IL17RB to Herpes Zoster Risk in Tofacitinib Treatment: Results of Genome‐Wide Association Study Meta‐Analyses

N. Bing, Y. Kochi, Baohong Zhang, 2021, Arthritis & rheumatology.

The Journal of Toxicological Sciences

M. Nishida, J. D. Clark, C. Bowman, 2002 .

Pharmacologic Inhibition of Tpl2 Blocks Inflammatory Responses in Primary Human Monocytes, Synoviocytes, and Blood*

K. Seidl, J. D. Clark, J. Telliez, 2007, Journal of Biological Chemistry.

In vitro allergen challenge of peripheral blood induces differential gene expression in mononuclear cells of asthmatic patients: inhibition of cytosolic phospholipase A2α overcomes the asthma-associated response

J. D. Clark, A. Hill, A. Dorner, 2008, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

Blockade of cytosolic phospholipase A2α prevents experimental autoimmune encephalomyelitis and diminishes development of Th1 and Th17 responses

M. Leach, Takao Shimizu, J. D. Clark, 2008, Journal of Neuroimmunology.

The cPLA2α inhibitor efipladib decreases nociceptive responses without affecting PGE2 levels in the cerebral spinal fluid

J. D. Clark, J. McKew, W. Duan, 2011, Neuropharmacology.

Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of (( S)-2,2-Difluorocyclopropyl)((1 R,5 S)-3-(2-((1-methyl-1 H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841).

Li Xing, Eddine Saiah, David Lin, 2018, Journal of medicinal chemistry.

Evaluation of the Short‐, Mid‐, and Long‐Term Effects of Tofacitinib on Lymphocytes in Patients With Rheumatoid Arthritis

Pinaki Biswas, Eun Bong Lee, Ernest Choy, 2019, Arthritis & rheumatology.

Reactions of functionalized sulfonamides: application to lowering the lipophilicity of cytosolic phospholipase A2alpha inhibitors.

J. McKew, E. A. Murphy, Xingwei Xu, 2009, Journal of medicinal chemistry.

Structure–activity relationships of indole cytosolic phospholipase A2α inhibitors: substrate mimetics

J. Alvarez, D. Joseph-McCarthy, J. D. Clark, 2003 .

Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition.

J. Bauman, J. D. Clark, M. Hegen, 2016, ACS chemical biology.

Network pharmacology of JAK inhibitors

S. Mostafavi, C. Benoist, D. Mathis, 2016, Proceedings of the National Academy of Sciences.

Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune Diseases.

S. Wright, J. D. Clark, M. Hegen, 2020, Journal of medicinal chemistry.

Demonstration of In Vitro to In Vivo Translation of a TYK2 Inhibitor That Shows Cross Species Potency Differences

J. D. Clark, M. Hegen, M. Dowty, 2020, Scientific Reports.

Molecular and Cellular Responses to the TYK2/JAK1 Inhibitor, PF 06700841, Reveal Reduction of Skin Inflammation in Plaque Psoriasis: TYK2/JAK1 inhibitor in plaque psoriasis.

E. Peeva, M. Suárez-Fariñas, C. Banfield, 2020, The Journal of investigative dermatology.

A fluorescence-based assay for fatty acid amide hydrolase compatible with high-throughput screening.

J. D. Clark, E. A. Murphy, Yuren Wang, 2005, Analytical biochemistry.

Variants Within STAT Genes Reveal Association with Anticitrullinated Protein Antibody-negative Rheumatoid Arthritis in 2 European Populations

L. Alfredsson, L. Padyukov, L. Klareskog, 2012, The Journal of Rheumatology.

Design and optimization of a series of 4-(3-azabicyclo[3.1.0]hexan-3-yl)pyrimidin-2-amines: Dual inhibitors of TYK2 and JAK1.

J. D. Clark, M. Hegen, Betsy S. Pierce, 2020, Bioorganic & medicinal chemistry.

Benzenesulfonamide indole inhibitors of cytosolic phospholipase A2alpha: optimization of in vitro potency and rat pharmacokinetics for oral efficacy.

J. D. Clark, J. McKew, W. Abraham, 2008, Bioorganic & medicinal chemistry.

Discovery of Ecopladib, an Indole Inhibitor of Cytosolic Phospholipase Α2α

S. Khor, J. D. Clark, J. McKew, 2007 .

Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: A randomized phase 2 study.

J. D. Clark, H. Valdez, M. Suárez-Fariñas, 2016, The Journal of allergy and clinical immunology.

Cytosolic Phospholipase A2α Blockade Abrogates Disease during the Tissue-Damage Effector Phase of Experimental Autoimmune Encephalomyelitis by Its Action on APCs

V. Kuchroo, M. Leach, J. D. Clark, 2011, The Journal of Immunology.

Thermodynamic characterization of cytosolic phospholipase A2 alpha inhibitors.

J. D. Clark, J. McKew, E. A. Murphy, 2008, Analytical biochemistry.

Discovery of Ecopladib, an indole inhibitor of cytosolic phospholipase A2alpha.

S. Khor, J. McKew, M. S. Ku, 2007, Journal of medicinal chemistry.

Cytosolic phospholipase A2α–deficient mice are resistant to experimental autoimmune encephalomyelitis

J. Leonard, M. Leach, Takao Shimizu, 2005, The Journal of experimental medicine.

Potential therapeutic uses of phospholipase A2 inhibitors

J. D. Clark, S. Tam, J. Clark, 2004 .

Cytosolic Phospholipase A2α–deficient Mice Are Resistant to Collagen-induced Arthritis

Takao Shimizu, J. D. Clark, M. Hegen, 2003, The Journal of experimental medicine.

–deficient Mice Are Resistant to Collagen-induced Arthritis

J. D. Clark, M. Hegen, N. Uozumi, 2003 .

Utility of cytosolic phospholipase A2a (cPLA2a) inhibitors in the treatment of asthma

J. D. Clark, Cara M. M. Williams, J. Clark, 2010 .

Inhibition of Cytosolic Phospholipase A 2 a: Hit to Lead Optimization

John C. McKew, S. Khor, J. D. Clark, 2006 .

Preclinical Evaluation of an Inhibitor of Cytosolic Phospholipase A2α for the Treatment of Asthma

M. Cazzola, J. D. Clark, M. Yeadon, 2012, Journal of Pharmacology and Experimental Therapeutics.

This information is current as Encephalomyelitis by Its Action on APCs Effector Phase of Experimental Autoimmune Abrogates Disease during the Tissue-Damage Blockade α 2 Cytosolic Phospholipase

V. Kuchroo, M. Leach, J. D. Clark, 2011 .

Cytosolic phospholipase A 2 – deficient mice are resistant to experimental autoimmune encephalomyelitis

J. Leonard, M. Leach, Takao Shimizu, 2005 .

A human CXCL13-induced actin polymerization assay measured by fluorescence plate reader.

J. D. Clark, Wenyan Miao, L. Bloom, 2010, Assay and drug development technologies.

Tri £ uoromethyl ketones and methyl £ uorophosphonates as inhibitors of group IV and VI phospholipases A 2 : structure-function studies with vesicle , micelle , and membrane assays 1

M. Gelb, E. Dennis, F. Ghomashchi, 1999 .

The balance of expression of PTPN22 splice forms is significantly different in rheumatoid arthritis patients compared with controls

T. Olsson, M. Khademi, L. Padyukov, 2012, Genome Medicine.

Inhibition of cytosolic phospholipase A2alpha: hit to lead optimization.

S. Khor, J. McKew, A. Mahadevan, 2006, Journal of medicinal chemistry.

Cytosolic phospholipase A2.

J. D. Clark, L. L. Lin, E. A. Nalefski, 1995, Journal of lipid mediators and cell signalling.

303 TYK2/JAK1 inhibition with PF-06700841 rapidly attenuates IL23/IL17 pathway genes and reverses the molecular phenotype in psoriasis

E. Peeva, M. Suárez-Fariñas, J. Krueger, 2017 .

Network pharmacology of JAK inhibitors

S. Mostafavi, C. Benoist, D. Mathis, 2016, Proceedings of the National Academy of Sciences.